Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Marc Le Bozec | M | - |
CYTOO SA
CYTOO SA Medical SpecialtiesHealth Technology CYTOO SA operates as a contract research organization which develops physiological cell-based assays. It focuses on developing, manufacturing, and commercializing new technologies for cell analysis for life sciences research community. The company has offices in Bethesda and Grenoble. The company was founded by François Chatelain, Alexandra Fuchs and Jacques Lewiner in 2008 and is headquartered in Grenoble, France. | 11 years |
Nicolas Fellmann | M | 55 | 1 years | |
Chiara Baccelli | M | 48 | 1 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Franck Grimaud | M | 58 |
Vivalis SA
Vivalis SA Pharmaceuticals: OtherHealth Technology Vivalis SA manufactures human and animal vaccines. The firm specializes in the research and development of vaccines and antiviral molecules, as well as in recombinant therapeutic protein and monoclonal antibody expression systems development. The firm's embryonic stem cells are used for practical applications in human and animal health. It also helps its clients in a case by case basis for the development of processes in the frame of service agreement. The company was founded in April 1999 and is headquartered in France. | 14 years |
Majid Mehtali | M | 63 |
Vivalis SA
Vivalis SA Pharmaceuticals: OtherHealth Technology Vivalis SA manufactures human and animal vaccines. The firm specializes in the research and development of vaccines and antiviral molecules, as well as in recombinant therapeutic protein and monoclonal antibody expression systems development. The firm's embryonic stem cells are used for practical applications in human and animal health. It also helps its clients in a case by case basis for the development of processes in the frame of service agreement. The company was founded in April 1999 and is headquartered in France. | 10 years |
Thibaut du Fayet | M | 56 | - | |
Céline Breda | F | 54 |
Vivalis SA
Vivalis SA Pharmaceuticals: OtherHealth Technology Vivalis SA manufactures human and animal vaccines. The firm specializes in the research and development of vaccines and antiviral molecules, as well as in recombinant therapeutic protein and monoclonal antibody expression systems development. The firm's embryonic stem cells are used for practical applications in human and animal health. It also helps its clients in a case by case basis for the development of processes in the frame of service agreement. The company was founded in April 1999 and is headquartered in France. | 8 years |
Evelyne Nguyen | F | 56 | 2 years | |
Dimitri Batsis | M | 58 | 5 years | |
Matthew P. Pando | M | 52 |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | 4 years |
Loïc Maurel | M | 69 |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | 4 years |
Brigitte Palestro | F | - | - | |
Hélène Dubourg | F | - |
Hautes Etudes Commerciales
| 4 years |
Arnaud Leclair | M | 51 |
Hautes Etudes Commerciales
| 4 years |
Pierre Miniou | M | - |
Vivalis SA
Vivalis SA Pharmaceuticals: OtherHealth Technology Vivalis SA manufactures human and animal vaccines. The firm specializes in the research and development of vaccines and antiviral molecules, as well as in recombinant therapeutic protein and monoclonal antibody expression systems development. The firm's embryonic stem cells are used for practical applications in human and animal health. It also helps its clients in a case by case basis for the development of processes in the frame of service agreement. The company was founded in April 1999 and is headquartered in France. | 10 years |
Stephen Brown | M | - |
Vivalis SA
Vivalis SA Pharmaceuticals: OtherHealth Technology Vivalis SA manufactures human and animal vaccines. The firm specializes in the research and development of vaccines and antiviral molecules, as well as in recombinant therapeutic protein and monoclonal antibody expression systems development. The firm's embryonic stem cells are used for practical applications in human and animal health. It also helps its clients in a case by case basis for the development of processes in the frame of service agreement. The company was founded in April 1999 and is headquartered in France. | 9 years |
Jean-Philippe Alex Combal | M | 58 |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | - |
Michel Gréco | M | 80 |
Vivalis SA
Vivalis SA Pharmaceuticals: OtherHealth Technology Vivalis SA manufactures human and animal vaccines. The firm specializes in the research and development of vaccines and antiviral molecules, as well as in recombinant therapeutic protein and monoclonal antibody expression systems development. The firm's embryonic stem cells are used for practical applications in human and animal health. It also helps its clients in a case by case basis for the development of processes in the frame of service agreement. The company was founded in April 1999 and is headquartered in France. | 7 years |
Jean-Luc Bélingard | M | 74 |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | 7 years |
Alain Munoz | M | 75 |
Vivalis SA
Vivalis SA Pharmaceuticals: OtherHealth Technology Vivalis SA manufactures human and animal vaccines. The firm specializes in the research and development of vaccines and antiviral molecules, as well as in recombinant therapeutic protein and monoclonal antibody expression systems development. The firm's embryonic stem cells are used for practical applications in human and animal health. It also helps its clients in a case by case basis for the development of processes in the frame of service agreement. The company was founded in April 1999 and is headquartered in France. | 11 years |
Thomas Grimaud | M | 46 |
Vivalis SA
Vivalis SA Pharmaceuticals: OtherHealth Technology Vivalis SA manufactures human and animal vaccines. The firm specializes in the research and development of vaccines and antiviral molecules, as well as in recombinant therapeutic protein and monoclonal antibody expression systems development. The firm's embryonic stem cells are used for practical applications in human and animal health. It also helps its clients in a case by case basis for the development of processes in the frame of service agreement. The company was founded in April 1999 and is headquartered in France. | 11 years |
Renee Grimaud | F | 84 |
Vivalis SA
Vivalis SA Pharmaceuticals: OtherHealth Technology Vivalis SA manufactures human and animal vaccines. The firm specializes in the research and development of vaccines and antiviral molecules, as well as in recombinant therapeutic protein and monoclonal antibody expression systems development. The firm's embryonic stem cells are used for practical applications in human and animal health. It also helps its clients in a case by case basis for the development of processes in the frame of service agreement. The company was founded in April 1999 and is headquartered in France. | - |
Joseph Grimaud | M | 83 |
Vivalis SA
Vivalis SA Pharmaceuticals: OtherHealth Technology Vivalis SA manufactures human and animal vaccines. The firm specializes in the research and development of vaccines and antiviral molecules, as well as in recombinant therapeutic protein and monoclonal antibody expression systems development. The firm's embryonic stem cells are used for practical applications in human and animal health. It also helps its clients in a case by case basis for the development of processes in the frame of service agreement. The company was founded in April 1999 and is headquartered in France. | 7 years |
Frédéric Grimaud | M | 59 |
Vivalis SA
Vivalis SA Pharmaceuticals: OtherHealth Technology Vivalis SA manufactures human and animal vaccines. The firm specializes in the research and development of vaccines and antiviral molecules, as well as in recombinant therapeutic protein and monoclonal antibody expression systems development. The firm's embryonic stem cells are used for practical applications in human and animal health. It also helps its clients in a case by case basis for the development of processes in the frame of service agreement. The company was founded in April 1999 and is headquartered in France. | 11 years |
Eric Jean Marie Leire | M | 66 | - | |
Deborah Choate | F | 61 |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | 5 years |
Frédéric Joël Desdouits | M | 57 |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | 3 years |
Guy-Charles Fanneau de la Horie | M | 64 | 6 years | |
Jean-Pierre Joseph Langevin | M | - |
Hautes Etudes Commerciales
| 1 years |
François Perron | M | - |
Hautes Etudes Commerciales
| 2 years |
Pascal Birman | M | - | - |
Statistics
Country | Connections | % of total |
---|---|---|
France | 27 | 87.10% |
Belgium | 4 | 12.90% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Philippe Rousseau
- Personal Network